Background We refer readers to the CY 2025 OPPS/ASC final rule with comment period (89 FR 94562 and 94563) for the previously estimated effects of changes to the REHQR Program for the CY 2025 reporting period and subsequent years
Cigna's list is unusually generous: "hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease, knee osteoarthritis, asthma, chronic obstructive pulmonary disease, metabolic dysfunction-associated steatotic liver disease/non-alcoholic fatty liver disease, polycystic ovarian syndrome, or coronary artery disease." The medication is used "concomitantly with behavioral modification and a reduced-calorie diet." Two details work in your favor
Genetic and metabolic factors of individuals
The emphasis remains on risk mitigation, clinical accountability, and alignment with established treatment standards
To view a copy of this licence, visit About this article Cite this article ORegan, G., Plummer, Z., Christie, B.R
If levels stay balanced, energy stays strong longer